Literature DB >> 9083266

Dual effect of lysophosphatidic acid on proliferation of glomerular mesangial cells.

F Gaits1, J P Salles, H Chap.   

Abstract

Among the variety of factors able to contribute to mesangial hypertrophy by altering mesangial cell growth, lysophosphatidic acid (LPA) is the focus of increasing attention. It is produced in plasma following platelet activation, as well as by mesangial cells stimulated by secretory phospholipase A2. As mitogenic/antimitogenic properties of LPA are already described in a variety of cells, knowledge of its specific actions on mesangial cells is of potential interest regarding the pathophysiology of glomerulus damage in situ. We tested the effect of LPA on cultured rat mesangial cell growth. At 10 to 20 microM, LPA stimulated thymidine incorporation as well as phosphorylation of mitogen-activated protein kinases (MAP-kinases) p42-p44 in dose- and time-dependent manner, which demonstrated a positive effect on cell proliferation. However, higher concentrations of LPA (100 microM) were unable to stimulate thymidine incorporation and partly inhibited the proliferative effect as well as p42-p44 phosphorylation evoked by serum. Finally, whereas lysophosphatidylcholine (10 to 20 microM) was lytic for mesangial cells, no cell lysis could be detected at the highest concentrations of LPA. Taken together, these results suggest that LPA exerts a dual effect on mesangial cell proliferation, which could be due to activation of distinct specific signaling pathways, in dose-dependent fashion. Specific actions of LPA able to modify mesangial cell proliferation in a positive or negative manner are also likely to influence the pathophysiological processes involved in the progression of glomerulosclerosis in the kidney.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083266     DOI: 10.1038/ki.1997.143

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

1.  Lysophosphatidic acid-mediated signal-transduction pathways involved in the induction of the early-response genes prostaglandin G/H synthase-2 and Egr-1: a critical role for the mitogen-activated protein kinase p38 and for Rho proteins.

Authors:  C O Reiser; T Lanz; F Hofmann; G Hofer; H D Rupprecht; M Goppelt-Struebe
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

2.  Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5.

Authors:  Huanchun Zhang; Agnieszka Bialkowska; Raluca Rusovici; Sengthong Chanchevalap; Hyunsuk Shim; Jonathan P Katz; Vincent W Yang; C Chris Yun
Journal:  J Biol Chem       Date:  2007-04-12       Impact factor: 5.157

Review 3.  Lysophosphatidic acid and renal fibrosis.

Authors:  Jean-Philippe Pradère; Julien Gonzalez; Julie Klein; Philippe Valet; Sandra Grès; David Salant; Jean-Loup Bascands; Jean-Sébastien Saulnier-Blache; Joost P Schanstra
Journal:  Biochim Biophys Acta       Date:  2008-04-11

4.  Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch.

Authors:  Fabienne Briand-Mésange; Véronique Pons; Sophie Allart; Julien Masquelier; Gaëtan Chicanne; Nicolas Beton; Bernard Payrastre; Giulio G Muccioli; Jérôme Ausseil; Jean-Luc Davignon; Jean-Pierre Salles; Hugues Chap
Journal:  J Biol Chem       Date:  2020-09-11       Impact factor: 5.157

5.  A lysophosphatidic acid analogue is revealed as a potent inhibitor of phosphatidylcholine synthesis, inducing apoptosis.

Authors:  Geneviéve Gueguen; Virginie Granci; Pierre Rogalle; Fabienne Briand-Mésange; Michéle Wilson; Alain Klaébé; François Tercé; Hugues Chap; Jean-Pierre Salles; Marie-Françoise Simon; Frédérique Gaits
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

6.  Lysophosphatidic acid increases mesangial cell proliferation in models of diabetic nephropathy via Rac1/MAPK/KLF5 signaling.

Authors:  Donghee Kim; Hui Ying Li; Jong Han Lee; Yoon Sin Oh; Hee-Sook Jun
Journal:  Exp Mol Med       Date:  2019-02-15       Impact factor: 8.718

7.  Screening for Potential Active Components of Fangji Huangqi Tang on the Treatment of Nephrotic Syndrome by Using Integrated Metabolomics Based on "Correlations Between Chemical and Metabolic Profiles".

Authors:  Xiao Liu; Qi-Gang Zhou; Xiao-Chai Zhu; Li Xie; Bao-Chang Cai
Journal:  Front Pharmacol       Date:  2019-10-22       Impact factor: 5.810

8.  Lysophosphatidic acid as a regulator of endometrial connective tissue growth factor and prostaglandin secretion during estrous cycle and endometrosis in the mare.

Authors:  Anna Szóstek-Mioduchowska; Natalia Leciejewska; Beata Zelmańska; Joanna Staszkiewicz-Chodor; Graça Ferreira-Dias; Dariusz Skarzynski
Journal:  BMC Vet Res       Date:  2020-09-17       Impact factor: 2.741

9.  Modified lipid metabolism and cytosolic phospholipase A2 activation in mesangial cells under pro-inflammatory conditions.

Authors:  Roberto Boi; Kerstin Ebefors; Marcus Henricsson; Jan Borén; Jenny Nyström
Journal:  Sci Rep       Date:  2022-05-05       Impact factor: 4.996

10.  Inhibition of ChREBP ubiquitination via the ROS/Akt-dependent downregulation of Smurf2 contributes to lysophosphatidic acid-induced fibrosis in renal mesangial cells.

Authors:  Donghee Kim; Ga-Young Nam; Eunhui Seo; Hee-Sook Jun
Journal:  J Biomed Sci       Date:  2022-05-10       Impact factor: 12.771

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.